Storys zum Thema Pharmaindustrie

Isomorphic Labs

Isomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic

London (ots/PRNewswire) - Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 ...

STADA Arzneimittel AG

3

Press Release STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market

Grünenthal Group

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal

Aachen, Germany & Toronto, Canada, (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, ...

MidEuropa

MIDEUROPA-BACKED DIAGNOSTYKA MAKES ITS WARSAW STOCK EXCHANGE DEBUT

London (ots/PRNewswire) - MidEuropa, a leading private equity investor with deep roots in Central Europe, announces that its portfolio company, Diagnostyka, a leading provider of medical diagnostic services in Poland, has debuted on the Warsaw Stock Exchange on Friday, February 7, 2025. The market closing price on the first day of trading puts Diagnostyka's market capitalisation at over €1 billion. Diagnostyka thus ...

Lyfegen; EVERSANA

Lyfegen and EVERSANA Collaborate to Revolutionize Drug Pricing and Access with AI-Driven Insights

Basel, Switzerland (ots/PRNewswire) - Lyfegen, a global innovator in drug market access, pricing, and rebate management, has announced a transformative collaboration with EVERSANA®, a leading provider of global commercial services to the life sciences industry, to revolutionize drug pricing and access through artificial intelligence-driven insights. By combining data ...

Norgine

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.

London (ots/PRNewswire) - Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare ...

Titian Software; Labguru

Keith Hale appointed as Group CEO to Unite Titian Software & Labguru (BioData)

London (ots/PRNewswire) - Keith Hale has been appointed as Group CEO of Titian Software and Labguru (BioData Inc.), two leading providers of laboratory data management solutions, as part of the goal to accelerate the future of digital lab operations. A well-known fintech executive, Keith brings 33 years of growth-focused software and technology leadership. He ...

LTS Lohmann Therapie-Systeme AG

LTS wins funding from BARDA’s Patch Forward Prize Competition for two partnerships

Grünenthal Group

Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer

BIAL SA

BIAL Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 - a Novel Therapy for GBA1 Parkinson's Disease

Porto, Portugal (ots/PRNewswire) - BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced that the first patient has completed the full dose regimen in the ACTIVATE Phase 2 study. BIA 28-6156 is a first-in-class, small molecule for once-daily oral ...

Norgine

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

London (ots/PRNewswire) - Back to media releases Next media release Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in ...

LAUDA DR. R. WOBSER GMBH & CO. KG

Antonio Manconi Ten Years With LAUDA Italia

RHEACELL GmbH und Co. KG

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Gerresheimer AG

Gerresheimer: FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU*

Accord Healthcare

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

London (ots/PRNewswire) - - Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases. - The EC approval follows a positive opinion issued on 19 October ...

Strides Pharma International AG

Strides Pharma Consolidates European Business-to-Business Operations in Switzerland

Grünenthal Group

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain

Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...

Grünenthal Group

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist

Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...

Epitomee Medical

Epitomee Medical to Present the Epitomee Breakthrough Oral Delivery Platform at PODD 2024 Conference

Caesarea, Israel (ots/PRNewswire) - Epitomee Medical Ltd. (TASE: EPIT) announces today that the company leadership intends to present Epitomee's Oral Delivery of Biologics Platform at the 14th Annual PODD Conference - Partnership Opportunities in Drug Delivery, taking place in Boston, MA, October 28-29, 2024. ...

STADA Arzneimittel AG

Press Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar

EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...

Norgine

Norgine Announces Appointment of New CEO Janneke van der Kamp

London (ots/PRNewswire) - Norgine (the "Company"), a leading European specialty pharmaceutical company, has today announced the appointment of Janneke van der Kamp as its new Chief Executive Officer (CEO), effective from 1 January 2025. Current CEO, Chris Bath, has stepped down from his role effective immediately. This change in leadership will support and enhance the Company's mission of bringing transformative medicines ...

Grünenthal Group

Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer

RHEACELL GmbH und Co. KG

RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU

Epitomee Medical

Epitomee Medical Announces FDA Clearance of its Capsule, Weight Management Device

Caesarea, Israel (ots/PRNewswire) - Epitomee's Ingestible Capsule, Offers a Safe and Effective Prescription Solution for Adults with BMI of 25-40 looking for Alternative Drug Free Solutions for Their Weight Management Needs alongside diet and exercise. Epitomee Medical Ltd. (TASE: EPIT), announced that the United States Food and Drug Administration (FDA) has officially ...